Filtered By:
Nutrition: Calcium

This page shows you your search results in order of date. This is page number 18.

Order by Relevance | Date

Total 1776 results found since Jan 2013.

Predictive values of coronary artery calcium and arterial stiffness for long-term cardiovascular events in patients with stable coronary artery disease
CONCLUSIONS: A CAC score ≥100 or a CAVI ≥ 9.0 predicts the long-term occurrence of MACEs in both asymptomatic and symptomatic patients with stable CAD. These two noninvasive tests can be used as screening tools to guide treatment for the prevention of future CV events.PMID:36448219 | DOI:10.1002/clc.23955
Source: Atherosclerosis - November 30, 2022 Category: Cardiology Authors: Thosaphol Limpijankit Sutipong Jongjirasiri Krissada Meemook Nattawut Unwanatham Ammarin Thakkinstian Jiraporn Laothamatas Source Type: research

IJERPH, Vol. 19, Pages 16064: Hypocalcemia Is a Common Risk Factor for Osteoporosis in Taiwanese Patients with Cushing & rsquo;s Syndrome
Conclusions: Our study found that lower serum calcium levels were common among patients with CS and osteoporosis. Furthermore, CS patients with HF or stroke had high proportion of hypocalcemia. Therefore, these patients must pay more attention to adequate calcium supplementation and undergo the appropriate osteoporosis drug treatment to reduce the risk of subsequent fracture and disability.
Source: International Journal of Environmental Research and Public Health - November 30, 2022 Category: Environmental Health Authors: Yung-Nien Chen Jia-Ruei Tsai Jung-Fu Chen Feng-Chih Shen Tags: Article Source Type: research

Statin therapy for primary prevention in men: What is the role for coronary artery calcium?
Statin therapy is widely prescribed for patients with established ASCVD (secondary prevention). Meta-analysis of randomized clinical trials (RCTs) show conclusively that statins substantially reduce recurrent major ASCVD events (myocardial infarction and stroke)1. More problematic is use of statins for patients without ASCVD (primary prevention). RCTs clearly demonstrate that statins can lower ASCVD for primary prevention in patients at higher risk for future vascular events2-4; however, the number needed to treat (NNT) to prevent one ASCVD event is much higher for primary prevention than for secondary prevention.
Source: Journal of Clinical Lipidology - November 23, 2022 Category: Lipidology Authors: Scott M. Grundy, Jijia Wong, Gloria L. Vega Source Type: research

Exploring the potential mechanism of Fritiliariae Irrhosae Bulbus on ischemic stroke based on network pharmacology and experimental validation
Conclusion: Based on network pharmacology, the effect of FIB in the treatment of ischemic strokes was discussed through the multi-component-multi-target-multi-pathway. The therapeutic effect and potential mechanisms of FIB on ischemic strokes were preliminarily explored, which provided a ground work for further researches on the pharmacodynamic material basis, mechanism of action and clinical application.
Source: Frontiers in Pharmacology - November 17, 2022 Category: Drugs & Pharmacology Source Type: research

How People With Diabetes Can Lower Stroke Risk
After spending nearly two decades trying to manage her Type 2 diabetes, Agnes Czuchlewski landed in the emergency room in 2015, with news that she’d just experienced a heart attack. She also learned that she had metabolic syndrome, a cluster of conditions that includes diabetes but also brings higher risk of heart disease and stroke. “Because I needed to lose quite a bit of weight when I was first diagnosed, I was focused on the number I saw on the scale, and then on my blood-sugar numbers,” recalls Czuchlewski, 68, who lives in New York City. “I didn’t realize other numbers came into play, li...
Source: TIME: Health - November 10, 2022 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized Disease healthscienceclimate Source Type: news

Late-Breaking Data from Pivotal Phase 3 PRECISION Study Demonstrates Significant and Sustained Effect of Aprocitentan on Lowering Blood Pressure for Patients with Difficult-to-Control Hypertension
RARITAN, NJ, November 7, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with Idorsia Ltd, today announced results from the Phase 3 PRECISION study, which found aprocitentan, an investigational, novel dual endothelin receptor antagonist (ERA), significantly reduced blood pressure (BP) and maintained the effect for up to 48 weeks when added to standardized combination background antihypertensive therapy in patients with difficult-to-control hypertension (sometimes referred to as resistant hypertension). These data were presented as a Late-Breaking Science presentation during the Amer...
Source: Johnson and Johnson - November 7, 2022 Category: Pharmaceuticals Source Type: news

Molecules, Vol. 27, Pages 7620: Quercetin & rsquo;s Effects on Glutamate Cytotoxicity
Molecules, Vol. 27, Pages 7620: Quercetin’s Effects on Glutamate Cytotoxicity Molecules doi: 10.3390/molecules27217620 Authors: Kade Riche Natalie R. Lenard The potentially therapeutic effects of the naturally abundant plant flavonoid quercetin have been extensively studied. An extensive body of literature suggests that quercetin’s powerful antioxidant effects may relate to its ability to treat disease. Glutamate excitotoxicity occurs when a neuron is overstimulated by the neurotransmitter glutamate and causes dysregulation of intracellular calcium concentrations. Quercetin has been shown ...
Source: Molecules - November 7, 2022 Category: Chemistry Authors: Kade Riche Natalie R. Lenard Tags: Review Source Type: research

Gualou Guizhi Decoction Improves Glucose Metabolism and Alleviates Microglia-Associated Inflammation after Cerebral Ischemia
CONCLUSION: GL enhanced the uptake and utilization of glucose in neural cells after CI/R. It exerted significant anti-inflammatory effects by regulating the polarization of microglia. These results provided further evidence supporting the clinical application of GL in the treatment of cerebral ischemic stroke.PMID:36317102 | PMC:PMC9617704 | DOI:10.1155/2022/9438250
Source: Evidence-based Complementary and Alternative Medicine - November 1, 2022 Category: Complementary Medicine Authors: Jizhou Zhang Jing Han Jun Zou Chang Jiang Chunquan Zhou Source Type: research

Annexins and cardiovascular diseases: Beyond membrane trafficking and repair
Front Cell Dev Biol. 2022 Oct 14;10:1000760. doi: 10.3389/fcell.2022.1000760. eCollection 2022.ABSTRACTCardiovascular diseases (CVD) remain the leading cause of mortality worldwide. The main cause underlying CVD is associated with the pathological remodeling of the vascular wall, involving several cell types, including endothelial cells, vascular smooth muscle cells, and leukocytes. Vascular remodeling is often related with the development of atherosclerotic plaques leading to narrowing of the arteries and reduced blood flow. Atherosclerosis is known to be triggered by high blood cholesterol levels, which in the presence o...
Source: Atherosclerosis - October 31, 2022 Category: Cardiology Authors: Nerea M éndez-Barbero Irene San Sebastian-Jaraba Rafael Bl ázquez-Serra Jose L Mart ín-Ventura Luis M Blanco-Colio Source Type: research

U.S. FDA Approves TECVAYLI ™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., October 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.1 TECVAYLI™ is a first-in-class, bispecific T-cell engager antibody that is administered as a subcutaneous treatment.1 This off-the-shelf (or ready to use) therapy uses innovative science to ac...
Source: Johnson and Johnson - October 25, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Gut Microbiota in Ischemic Stroke: Role of Gut Bacteria-Derived Metabolites
AbstractIschemic stroke (IS) remains a leading cause of death and long-term disability globally. Several mechanisms including glutamate excitotoxicity, calcium overload, neuroinflammation, oxidative stress, mitochondrial damage, and apoptosis are known to be involved in the pathogenesis of IS, but the underlying pathophysiology mechanisms of IS are not fully clarified. During the past decade, gut microbiota were recognized as a key regulator to affect the health of the host either directly or via their metabolites. Recent studies indicate that gut bacterial dysbiosis is closely related to hypertension, diabetes, obesity, d...
Source: Translational Stroke Research - October 24, 2022 Category: Neurology Source Type: research